Author

Anna Alonso‐Saladrigues

Observed names: A, Alonso-Saladrigues, A. Alonso-Saladrigues, A. Alonso‐Saladrigues, Alonso-Saladrigues A, Alonso-Saladrigues, Anna, Anna Alonso-Saladrigues

Institutions: Hospital Sant Joan de Déu Barcelona, Instituto de Salud Carlos III, Grupo Español de Trasplante Hematopoyético y Terapia Celular, Centre for Biomedical Network Research on Rare Diseases, Institut de Recerca Sant Joan de Déu, Universitat de Barcelona

Observed institutions: Hospital Sant Joan de Déu Barcelona, Instituto de Salud Carlos III, Grupo Español de Trasplante Hematopoyético y Terapia Celular, Centre for Biomedical Network Research on Rare Diseases, Institut de Recerca Sant Joan de Déu, Universitat de Barcelona

ORCID: 0000-0002-3195-5470

Observed ORCID: 0000-0002-3195-5470

OpenAlex ID: A5069368748

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

2020 · Valentín Ortíz-Maldonado, Susana Rives, et al. · Molecular Therapy · 164

PDF

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

2025 · Sara K. Silbert, Alexander W. Rankin, et al. · Blood · 46

PDF

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

2021 · Valentín Ortiz-Maldonado, Susana Rives, et al. · Journal for ImmunoTherapy of Cancer · 27

PDF

Results of ARI ‐0001 CART19 cell therapy in patients with relapsed/refractory CD19 ‐positive acute lymphoblastic leukemia with isolated extramedullary disease

2022 · Valentín Ortiz‐Maldonado, Anna Alonso‐Saladrigues, et al. · American Journal of Hematology · 24

Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

2024 · Águeda Molinos-Quintana, Anna Alonso-Saladrigues, et al. · Frontiers in Immunology · 23

PDF

Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia

2020 · A. Deyà-Martínez, A. Alonso-Saladrigues, et al. · Bone Marrow Transplantation · 21

PDF

Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

2023 · Marina Caballero-Bellón, Anna Alonso-Saladrigues, et al. · Frontiers in Immunology · 15

Paediatric patients with acute leukaemia and KMT 2A ( MLL ) rearrangement show a distinctive expression pattern of histone deacetylases

2018 · Nerea Vega‐García, Roberta Malatesta, et al. · British Journal of Haematology · 14

Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults

2025 · Víctor Galán-Gómez, Berta González-Martínez, et al. · Experimental Hematology and Oncology · 12

PDF

Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening

2015 · R. Berrueco, A. Alonso‐Saladrigues, et al. · Pediatric Blood & Cancer · 12

Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia

2021 · Montserrat Mesegué, Anna Alonso‐Saladrigues, et al. · Hematological Oncology · 11

Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit

2021 · Marina Caballero, Anna Faura, et al. · European Journal of Pediatrics · 9

Aplastic Crisis Secondary to Parvovirus B19 Infection as the First Manifestation of an Undiagnosed Hereditary Spherocytosis

2015 · Anna Alonso-Saladrigues, Albert Català, et al. · Journal of Pediatric Hematology/Oncology · 7

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

2023 · Sara K. Silbert, Cynthia Harrison, et al. · Blood · 5

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

2025 · Ariadna Bartoló-Ibars, Andrea Aran, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

Successful allogeneic CD34+ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

2024 · Águeda Molinos-Quintana, Nuria Martínez-Cibrian, et al. · Bone Marrow Transplantation · 3

Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients

2024 · Maria-Eva Mingot-Castellano, Juan Luis Reguera-Ortega, et al. · Journal of Clinical Medicine · 3

PDF

Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults

2025 · Caballero-Bellón M, Bobillo-Perez S, et al. · Biomarkers · 2

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

2024 · Valentin Ortiz-Maldonado, Jacques-Emmanuel Galimard, et al. · Blood · 2

PDF

Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions

2016 · Mariona F. de Sevilla, Albert Català, et al. · Pediatric Blood & Cancer · 2

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

2024 · Giorgio Ottaviano, Anna Alonso-Saladrigues, et al. · Blood · 1

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

2024 · Águeda Molinos-Quintana, Anna Alonso-Saladrigues, et al. · Frontiers in Immunology · 1

PDF

Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC

2026 · Víctor Galán-Gómez, Odelaisy León-Triana, et al. · Bone Marrow Transplantation

BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series

2026 · Georgina Morón-Cazalilla, Marina Pons-Espinal, et al. · Journal of Pediatric Hematology/Oncology

Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy

2026 · Valentín Ortiz-Maldonado, Jacques-Emmanuel Galimard, et al. · Blood Advances

PDF

Works count: 43

Citation count: 407

H-index: 11

I10-index: 11